Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion

This article was originally published in PharmAsia News

Executive Summary

Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan

You may also be interested in...



Otsuka Searches For Value In Portfolio Through Patient Compliance Technology

Alliance with Lundbeck emphasizes search for innovation in all corners of CNS research.

Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel

TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia

Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel

TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia

Related Content

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel